Cardiac amyloidosis: the stiffening heart that is not just old age, and the new drug that slows it
Last updated September 3, 2026.
Cardiac amyloidosis is a heart made stiff by an abnormal protein, amyloid, building up in its walls. The stiff heart cannot relax and fill properly, and the result is heart failure with a normal-looking pumping fraction: breathlessness, ankle swelling, and exhaustion, often for years before the true diagnosis lands. It comes in two main types. The wild-type ATTR form appears in older adults, mostly men, and was for decades dismissed as just old age; the hereditary form runs in families. The AL type, driven by a blood-cell disorder, is the urgent cousin. The reason this condition matters so much now is that it finally has treatments: tafamidis, a daily capsule, slows the ATTR form measurably, and newer silencing drugs are arriving behind it. The earlier it starts, the more heart it saves, which is why the diagnosis is being hunted earlier. The clues that raise suspicion: heart failure with a normal pump fraction on echo, carpal tunnel syndrome in both wrists years earlier, a narrow pulse pressure, and an ECG with low voltage despite a thick heart wall. Diagnosis is now usually made without a biopsy, using a special heart scan.
What does it look like?
The heart failure picture first: breathlessness on exertion, then at rest, ankles swelling by evening, exhaustion, and fluid tablets helping only partly. Around the heart, the same protein causes its signature elsewhere: carpal tunnel in both wrists, often years before; a numb, tingling walk from nerve involvement in the hereditary form; and an aortic valve that narrows in the same age group. Many people carry a story of being told their heart failure was age or blood pressure, and the amyloidosis answer arriving years late.
Why does it happen?
A normal protein, transthyretin, made by the liver, falls apart and misfolds, and the misfolded pieces deposit in the heart as amyloid. In wild-type ATTR this is simply what transthyretin does with age in susceptible people, mostly men over 65, and nobody knows why them; in the hereditary form a gene variant drives it, and the family question gets a genetic counseling answer. It is not caused by anything you did, and it is not contagious.
How is it treated?
- Tafamidis is the anchor for ATTR. A daily capsule that stabilizes the protein so it stops depositing, shown to slow the disease and extend life. It works best started early, which is the entire argument for finding this diagnosis sooner.
- The fluid is managed gently. Water tablets for the breathlessness and swelling, dosed carefully: the stiff heart needs enough filling pressure, so the diuretic sweet spot is narrower than in ordinary heart failure.
- Some common heart medicines do not suit. Beta-blockers, ACE inhibitors, and digoxin are often poorly tolerated or harmful in amyloid hearts, so the usual heart-failure pillbox gets edited, not copied.
- The rhythm and the nerve symptoms get their own care. Atrial fibrillation is common and gets anticoagulation; pacemakers help some; carpal tunnel releases and nerve care are part of the same condition, not separate bad luck.
- Transplant is for the few. Heart, or heart and liver, for selected advanced cases. Most management is medical, at home, on a clinic schedule.
When does it need the prompt review?
Worsening breathlessness, especially lying flat, a fast weight gain from fluid, or fainting deserve a review within days, because the diuretic balance in this condition is fine and needs tuning. A racing irregular pulse or a faint is same-day. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
Was I misdiagnosed for four years?
The fair answer: you were early-arrived rather than misdiagnosed. Wild-type ATTR has spent decades hiding inside ordinary heart failure, because the echo looks like common age-related stiffness and, until recently, there was neither an easy test nor a specific treatment, so the hunt was rarely on. Your four years of half-responding tablets were, in hindsight, the condition's signature. The cardiologist who ordered the special scan gave you the benefit of a decade that finally made this diagnosis findable and treatable. The lesson worth passing on is for others: heart failure with a normal pump fraction, especially with both wrists having had carpal tunnel, now deserves the amyloid question.
Is tafamidis worth it at 72?
Yes, and you are precisely who it is for. The trial evidence includes people in their seventies and older, and it shows the drug slows the disease, keeps people out of hospital, and extends life. The honest framing: it is a brake, not a cure, because heart wall already stiffened does not un-stiffen, which is the entire argument for starting now rather than next year. It is a daily capsule, generally well tolerated, with monitoring at intervals. The question worth asking the team is about cost coverage, because it is an expensive drug, and the systems for that are better than they were.
Why did the usual heart failure tablets never quite work?
Because your heart failure is a different mechanism from the common form. Ordinary heart failure is a pump that has gone weak, and the standard tablets are built for that. Yours is a heart gone stiff: the pump squeezes but cannot relax and fill, and the protein causing the stiffness is untouched by the standard drugs. Worse, some of the usual pills, beta-blockers and the blood-pressure families, are often poorly tolerated by an amyloid heart, which is why your pillbox is being edited rather than added to. The treatment that matches your mechanism is the stabilizer capsule plus carefully tuned water tablets.
Will my children get this?
Almost certainly not from you, and the reassurance is worth having precisely. There are two types: the wild-type ATTR form, which you have, is a condition of aging transthyretin and is not inherited, so your children carry the ordinary population risk. The hereditary form, driven by a gene variant, is the one where family screening matters. Your cardiologist will confirm the type from the tests already done, and if any doubt remains, genetic testing settles it. Ask at the next visit, hear the words wild-type, and let your children off the hook.
What does the future actually look like for me?
The honest picture, which is better than the diagnosis day felt: this is a chronic condition now, managed at home, with a drug that slows it measurably. The next years, on treatment, typically look like the current ones with a brake applied: the breathlessness and fluid managed with tuned water tablets, hospital visits for rhythm and fluid reviews, and the protein's advance slowed to a fraction of its untreated pace. The things worth reporting promptly are worsening breathlessness, fast weight gain from fluid, faints, or a racing irregular pulse. Research is moving fast in this field, and the drug you are starting is the first of several, which matters if the brake ever needs a sibling.
Were the carpal tunnel surgeries connected? Both my wrists were done years ago.
Very probably yes, and you are holding one of the strangest clues in medicine. The same amyloid protein deposits in the wrist's carpal tunnel years, often a decade, before the heart declares itself, and both-wrists carpal tunnel in an older man is now a recognized early signature of wild-type ATTR. Nobody could have known at the time; the connection has only recently become standard knowledge. For you it changes nothing about the wrists, but it is worth telling your children and your cardiologist confirmed it, because in the hereditary families, that clue is the reason some relatives get screened before any heart symptom arrives.